Abstracts tagged "cytokines"

Abstract Number: 901 • 2012 ACR/ARHP Annual Meeting
Colony-Stimulating Factor (CSF) Receptor 1 Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-34 On Myeloid Differentiation and Gene Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis
Samuel Garcia¹, Linda M. Hartkamp², Inge E. van Es², Haishan Lin³, Li Long³, Emma L. Masteller³, Brian R. Wong³, Paul P. Tak⁴ and Kris A. Reedquist², ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Five Prime Therapeutics, Inc., South San Francisco, CA, ⁴Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Disease activity and response to therapy in RA correlates with changes in synovial macrophage numbers and their products. M-CSF or IL-34 stimulation of their…
Abstract Number: 218 • 2012 ACR/ARHP Annual Meeting
Proteomics Study of a Phase 1b Trial with an Anti-IFN-α Monoclonal Antibody Indicates Association of Soluble Interleukin 2 Receptor with Type I Interferon Activity in Patients with Dermatomyositis or Polymyositis
Xiang Guo¹, Brandon W. Higgs¹, Wei Zhu², Yihong Yao¹ and Wendy White³, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Science, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune, Gaithersburg, MD
Background/Purpose: To evaluate downstream effects of an anti-IFN-α monoclonal antibody (mAb) in adult dermatomyositis (DM) and polymyositis (PM) patients using serum proteomics and gene expression…
Abstract Number: 2335 • 2012 ACR/ARHP Annual Meeting
Increased TSLP Expression in Joints of Rheumatoid Arthritis Patients Causes Increased Activation of Intra-Articular Myeloid Dendritic Cells with Enhanced Th1 and Th17 Cell Activity
F.M. Moret¹, C.E. Hack², T.R.D.J. Radstake³, J.W.J. Bijlsma¹, F.P.J.G. Lafeber¹ and J.A.G. van Roon⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Immunology, UMC Utrecht, Utrecht, Netherlands, ³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Thymic stromal lymphopoietin (TSLP) is well known for its potent activation of myeloid dendritic cells (mDCs) to induce Th2-mediated immune responses. Administration of TSLP…
Abstract Number: 1518 • 2012 ACR/ARHP Annual Meeting
Damage-Associated Endogenous TLR4 Ligand Fibronectin-EDA Is Overexpressed in Scleroderma and Drives Persistent Fibrosis Via TLR4 and Inhibition of TLR4 Prevents and Reverses Experimental Dermal Fibrosis: Novel Target for Scleroderma Therapy
Swati Bhattacharyya¹, Zenshiro Tamaki², Wenxia Wang³, Paul Hoover⁴, Adam Booth⁵, Alyssa Dreffs⁶, Monique E. Hinchcliff⁷, Feng Fang⁸, Spiro Getsios⁴, Hang Yin⁹, Eric S. White⁶ and John Varga¹⁰, ¹Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ²Medicine, Rheumatology, Northwestern Univ Med School, Chicago, IL, Chicago, IL, ³Medicine/Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁵Ann Arbor, MI, ⁶Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI, ⁷Division of Rheumatology, Northwestern Univ Med School, Chicago, IL, ⁸Rheumatology Division, Northwestern University, Chicago, IL, ⁹University of Colorado at Boulder, Boulder, CO, ¹⁰Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Recent studies implicate innate immune signaling and Toll like receptor-4 (TLR4) in fibrogenesis. We hypothesized that injury in scleroderma leads to tissue accumulation of…
Abstract Number: 878 • 2012 ACR/ARHP Annual Meeting
Differential Regulation of Cytokines by Extracellular-Signal Regulated Kinase and c-Jun N-Terminal Kinase in Map Kinase Kinase-3 and -6 Deficiency
Deepa Hammaker¹, Katharyn Topolewski², Monica Guma³, David L. Boyle⁴ and Gary S. Firestein⁵, ¹MC 0656, UCSD School of Medicine, La Jolla, CA, ²UCSD School of Medicine, La Jolla, CA, ³Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁴Div of Rheum, UCSD School of Medicine, La Jolla, CA, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: p38 inhibitors have limited efficacy in rheumatoid arthritis (RA), possibly because p38 blockade suppresses IL-10 production and increases JNK and ERK phosphorylation in…
Abstract Number: 87 • 2012 ACR/ARHP Annual Meeting
Prediction of Mortality in Rheumatoid Arthritis Using a Serum Cytokine Profile
Agustin Escalante¹, Roy W. Haas¹, Daniel F. Battafarano² and Inmaculada Del Rincon³, ¹Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center, San Antonio, TX
Background/Purpose: Cytokines are important in the pathogenesis of RA. Their concentration in the serum rises immediately prior to RA onset, and may be associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.